Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on June 26, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Section 7.01 text contains only a filing-liability disclaimer.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Section 7.01 text contains only a filing-liability disclaimer
- No substantive Regulation FD disclosure or investor-actionable information identified
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted RP1 BLA resubmission for accelerated approval in advanced melanoma, removing the prior completeness hurdle
- FDA action date August 2, 2026, creating a near-term binary regulatory catalyst
- Advisory committee expected in late July, adding public scrutiny and potential volatility before the decision
- Application relies on IGNYTE data in patients progressing after anti-PD-1 therapy, targeting substantial unmet need
- Approval would validate RP1 commercially, while FDA review and clinical efficacy remain key risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.